Oncology | IND Enabling Drugs | KOREA, REPUBLIC OF

Peptron

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC

Lead Product(s): PAb001-ADC

Therapeutic Area: Oncology Product Name: PAb001-ADC

Highest Development Status: IND Enabling Product Type: Large molecule

Partner/Sponsor/Collaborator: Qilu Pharmaceutical Co., Ltd.

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement April 16, 2021

Details:

Under the terms of the agreement, Peptron grants Qilu an exclusive global right and license to develop, manufacture, sell, and commercialize PAb001-ADC for the treatment of cancers.

Samsung Biologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA

Lead Product(s): EU101

Therapeutic Area: Oncology Product Name: EU101

Highest Development Status: IND Enabling Product Type: Large molecule

Partner/Sponsor/Collaborator: National OncoVenture

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2021

Details:

Studied by NOV and Eutilex with humanized mice, EU101(NOV1801), effectively eradicated human tumors and showed synergistic anti-tumor activity with immune checkpoint blockade.